Phibro Animal Health Reports Q3 Fiscal 2026 Net Sales of $383.5M, Raises Full-Year Guidance

Key Takeaways

• Q3 net sales $383.5M, up 10% YoY.
• Animal Health sales $291.2M, grew 13% driven by MFA and vaccines.
• Revolving credit facility expanded by $125M to $435M, boosting liquidity.
• Full-year sales guidance raised to $1.46‑$1.50B; adjusted EBITDA $247‑$255M.
• Gross margin rose 270 bps to 32.8% despite higher SG&A.

Pulse Analysis

Phibro Animal Health’s third‑quarter performance underscores the resilience of the animal‑health market, where demand for both feed‑additive (MFA) solutions and veterinary vaccines remains robust. The company’s 13% segment sales surge reflects the successful integration of the MFA portfolio acquired in late 2024 and a notable 16% lift in vaccine sales, driven by international swine and companion‑animal markets. This organic growth, combined with modest pricing gains, helped push gross margin up 270 basis points to 32.8% of net sales, a rare achievement amid rising input costs.

On the balance sheet, Phibro strengthened its liquidity by expanding its revolving credit facility by $125 million, raising the total commitment to $435 million. The additional capacity not only cushions short‑term working‑capital needs but also provides flexibility for strategic investments, such as the newly launched Sustainable Solutions Platform. While SG&A expenses rose 14% due to higher employee costs, the company’s free cash flow of $12.8 million and a gross leverage ratio of 3.1× indicate a manageable debt profile, especially as adjusted EBITDA climbs to $60.8 million.

Looking ahead, the raised full‑year guidance—projecting $1.46‑$1.50 billion in sales and up to $255 million in adjusted EBITDA—signals confidence that the growth momentum will continue. Investors will watch how Phibro leverages its sustainability initiatives and expanded credit line to fund product innovation and potential acquisitions. In a sector where regulatory shifts and feed‑ingredient pricing can be volatile, the company’s ability to deliver double‑digit growth while improving margins positions it favorably against peers.